202 related articles for article (PubMed ID: 33253791)
1. PIN1 facilitates ubiquitin-mediated degradation of serine/threonine kinase 3 and promotes melanoma development via TAZ activation.
Kim G; Bhattarai PY; Lim SC; Kim JY; Choi HS
Cancer Lett; 2021 Feb; 499():164-174. PubMed ID: 33253791
[TBL] [Abstract][Full Text] [Related]
2. Identification of Prolyl isomerase Pin1 as a novel positive regulator of YAP/TAZ in breast cancer cells.
Khanal P; Yeung B; Zhao Y; Yang X
Sci Rep; 2019 Apr; 9(1):6394. PubMed ID: 31015482
[TBL] [Abstract][Full Text] [Related]
3. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation.
Lin KC; Moroishi T; Meng Z; Jeong HS; Plouffe SW; Sekido Y; Han J; Park HW; Guan KL
Nat Cell Biol; 2017 Jul; 19(8):996-1002. PubMed ID: 28752853
[TBL] [Abstract][Full Text] [Related]
4. TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation.
Matsushita A; Sato T; Mukai S; Fujishita T; Mishiro-Sato E; Okuda M; Aoki M; Hasegawa Y; Sekido Y
Oncogene; 2019 Mar; 38(11):1966-1978. PubMed ID: 30401981
[TBL] [Abstract][Full Text] [Related]
5. Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ).
Gandhirajan RK; Jain M; Walla B; Johnsen M; Bartram MP; Huynh Anh M; Rinschen MM; Benzing T; Schermer B
J Biol Chem; 2016 May; 291(22):11596-607. PubMed ID: 27048650
[TBL] [Abstract][Full Text] [Related]
6. The nonreceptor tyrosine kinase c-Src attenuates SCF(β-TrCP) E3-ligase activity abrogating Taz proteasomal degradation.
Shanzer M; Adler J; Ricardo-Lax I; Reuven N; Shaul Y
Proc Natl Acad Sci U S A; 2017 Feb; 114(7):1678-1683. PubMed ID: 28154141
[TBL] [Abstract][Full Text] [Related]
7. CDK7 regulates organ size and tumor growth by safeguarding the Hippo pathway effector Yki/Yap/Taz in the nucleus.
Cho YS; Li S; Wang X; Zhu J; Zhuo S; Han Y; Yue T; Yang Y; Jiang J
Genes Dev; 2020 Jan; 34(1-2):53-71. PubMed ID: 31857346
[TBL] [Abstract][Full Text] [Related]
8. COT phosphorylates prolyl-isomerase Pin1 to promote tumorigenesis in breast cancer.
Kim G; Khanal P; Kim JY; Yun HJ; Lim SC; Shim JH; Choi HS
Mol Carcinog; 2015 Jun; 54(6):440-8. PubMed ID: 24265246
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
Chen M; Wang M; Xu S; Guo X; Jiang J
Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylation and Stabilization of PIN1 by JNK Promote Intrahepatic Cholangiocarcinoma Growth.
Lepore A; Choy PM; Lee NCW; Carella MA; Favicchio R; Briones-Orta MA; Glaser SS; Alpini G; D'Santos C; Tooze RM; Lorger M; Syn WK; Papakyriakou A; Giamas G; Bubici C; Papa S
Hepatology; 2021 Nov; 74(5):2561-2579. PubMed ID: 34048060
[TBL] [Abstract][Full Text] [Related]
11. PYK2 negatively regulates the Hippo pathway in TNBC by stabilizing TAZ protein.
Kedan A; Verma N; Saroha A; Shreberk-Shaked M; Müller AK; Nair NU; Lev S
Cell Death Dis; 2018 Sep; 9(10):985. PubMed ID: 30250159
[TBL] [Abstract][Full Text] [Related]
12. SUV39H1/DNMT3A-dependent methylation of the RB1 promoter stimulates PIN1 expression and melanoma development.
Kim G; Kim JY; Lim SC; Lee KY; Kim O; Choi HS
FASEB J; 2018 Oct; 32(10):5647-5660. PubMed ID: 29750576
[TBL] [Abstract][Full Text] [Related]
13. Role of the Hippo pathway and mechanisms for controlling cellular localization of YAP/TAZ.
Kwon H; Kim J; Jho EH
FEBS J; 2022 Oct; 289(19):5798-5818. PubMed ID: 34173335
[TBL] [Abstract][Full Text] [Related]
14. Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 directly binds and stabilizes Nrf2 in breast cancer.
Saeidi S; Kim SJ; Guillen-Quispe YN; Jagadeesh ASV; Han HJ; Kim SH; Zhong X; Piao JY; Kim SJ; Jeong J; Shin YJ; Cha YJ; Lee HB; Han W; Min SH; Tian W; Kitamura H; Surh YJ
FASEB J; 2022 Jan; 36(1):e22068. PubMed ID: 34918396
[TBL] [Abstract][Full Text] [Related]
15. The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer.
Di Benedetto A; Mottolese M; Sperati F; Ercolani C; Di Lauro L; Pizzuti L; Vici P; Terrenato I; Sperduti I; Shaaban AM; Sundara-Rajan S; Barba M; Speirs V; De Maria R; Maugeri-Saccà M
Oncotarget; 2016 Jul; 7(28):43188-43198. PubMed ID: 27248471
[TBL] [Abstract][Full Text] [Related]
16. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
[TBL] [Abstract][Full Text] [Related]
17. CDK5-dependent phosphorylation and nuclear translocation of TRIM59 promotes macroH2A1 ubiquitination and tumorigenicity.
Sang Y; Li Y; Zhang Y; Alvarez AA; Yu B; Zhang W; Hu B; Cheng SY; Feng H
Nat Commun; 2019 Sep; 10(1):4013. PubMed ID: 31488827
[TBL] [Abstract][Full Text] [Related]
18. YAP/TAZ Activation Drives Uveal Melanoma Initiation and Progression.
Li H; Li Q; Dang K; Ma S; Cotton JL; Yang S; Zhu LJ; Deng AC; Ip YT; Johnson RL; Wu X; Punzo C; Mao J
Cell Rep; 2019 Dec; 29(10):3200-3211.e4. PubMed ID: 31801083
[TBL] [Abstract][Full Text] [Related]
19. Somatic Hypermutation of the
Zhang X; Tang JZ; Vergara IA; Zhang Y; Szeto P; Yang L; Mintoff C; Colebatch A; McIntosh L; Mitchell KA; Shaw E; Rizos H; Long GV; Hayward N; McArthur GA; Papenfuss AT; Harvey KF; Shackleton M
Mol Cancer Res; 2019 Jul; 17(7):1435-1449. PubMed ID: 30833299
[TBL] [Abstract][Full Text] [Related]
20. A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ.
Tan G; Cao X; Dai Q; Zhang B; Huang J; Xiong S; Zhang Yy; Chen W; Yang J; Li H
Oncotarget; 2015 Apr; 6(11):8676-86. PubMed ID: 25895125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
